Product Catalog
Generic Norvasc (Amlodipine, Norvasc® equivalent)
Amlodipine is in a class of medications called calcium channel blockers. Amlodipine widens the blood vessels, making it easier for the heart to pump and reducing its workload. Amlodipine is used to treat hypertension (high blood pressure) and to treat angina (chest pain). Amlodipine may also be used for purposes other than those listed in this medication guide.
This product will arrive to you in 14-24 business days (free shipping worldwide)
10mg
| Quantity | Price | Price per pill | Returning customer price | Bonus | |
|---|---|---|---|---|---|
| 10 | € 36.19 | € 3.62 | € 32.34 | ---- | Add to cart |
| 20 | € 38.50 | € 1.93 | € 34.65 | ---- | Add to cart |
| 30 | € 40.81 | € 1.36 | € 36.19 | ---- | Add to cart |
Drug Medical Information
AGE AND BEHAVIOR: RESEARCH METHODS - COHORT AND TIME OF MEASUREMENT CONFOUNDED - CROSS-SEQUENTIAL STRATEGY – INTERPRETATION
Recall again that this design, along with the others, was developed to disentangle three interacting effects: age, cohort, and time of measurement. It is not often recognized that these designs developed to do just this have been used with the paradoxical assumption that the effects are not confounded. When so used, each design becomes limited in its intended purpose. When the designs are used together and no such assumptions are made, however, they are valuable.
As described, the two main effects are age-cohort (A 4- a compared to B + b . . . G + g) and age-time of measurement (I compared to II). There is much to learn from these two effects, as, for example, the change in test scores over time seen among the different age-cohort groups. This tells us much more than does a simple change in score over time for one group (longitudinal comparison), or simple differences in score among several groups (cross-sectional comparison). However, when disentanglement of confounded effects has been attempted, controversy has resulted.
Here are assumptions that have been made in one of several cross-sequential studies (e.g., Schaie and Labouvie): First, the age and cohort confound (A + a versus B + b, C + c . . .) is a cohort effect only; age is not a factor. If this assumption was necessarily true, then all cross-sectional studies could be carried out without further issue since only cohort or cultural effects would be measured, not age. The second assumption is that the age and time of measurement confound (I versus II) is a time of measurement effect only; again age is not a factor. The fact that the people of Test Time 2 are older than Test Time 1 is assumed not important. Thus, by these assumptions, the cross-sequential design is made to reflect only cohort and time of measurement effects. How relevant is this design to research in aging when the assumptions place age itself into a category of nonconsideration? Cross-sequential designs are valuable, but only without the above assumptions; they permit descriptions of the changes of the different age-cohort groups.
*432\220\8*
